Tevogen Bio(US:TVGN) Globenewswire·2026-03-13 16:30Core Insights - Tevogen Bio Holdings Inc. has made significant advancements in its artificial intelligence platform, Tevogen.AI, aimed at improving drug development by identifying effective biological targets before costly clinical trials [1][11]. Database and Data Points - The company has developed a proprietary database containing over 655 million peptide sequences from approximately 24 million proteins, equating to nearly 16 billion data points across various disease areas [2]. Improved Prediction Accuracy - The PredicTcell™ model has shown improved accuracy, with recall increasing from 87% to 92% and precision rising from 40% to 48%, indicating a more effective identification of immune targets [14]. The model is now nearly 20 times more robust than its initial version, trained on 1.8 million data points [3][14]. Continuous Learning and AI Agents - Tevogen.AI operates three production AI agents that create a continuous learning loop between AI predictions and biological validation, enhancing future performance [4]. Partnership Strategy - As predictive accuracy improves, the company plans to explore partnerships with pharmaceutical firms to advance selected peptide candidates for production and development [5]. Long-term Goals - The company aims to reduce trial-and-error in immunotherapy design and enhance success rates while lowering development risks, which could create significant long-term value [6]. Pipeline and Therapeutic Areas - Tevogen Bio's pipeline includes initiatives in virology, oncology, and neurology, utilizing the proprietary ExacTcell™ platform [7]. The company is also exploring future strategic initiatives in domestic generics, biosimilars, medical devices, and innovative insurance solutions [9]. Technological Integration - Tevogen.AI leverages cloud and data services from major technology providers like Microsoft and Databricks to accelerate drug discovery and optimize clinical trial design [8].